



24 October 2023

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call Notification

ImpediMed Limited (ASX:IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 30 September 2023 on Tuesday 31st October 2023.

Investors are invited to join a live conference call hosted by Managing Director and CEO Rick Valencia and CFO Tim Cruickshank at 9:00am (AEDT) on Tuesday 31st October 2023. A live Q&A will follow the presentation.

Questions can be asked in advance by sending to investorrelations@impedimed.com or investors can request to ask a question live during the call. Due to the expected high volume of questions to be received during the conference call, not everyone may get a chance to speak live, however, the Company will endeavor to respond to as many as possible in the allocated time.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/10034410-qybv65.html>

Registered participants will receive a calendar notification with dial in details and a PIN for fast-track access to the call.

Approved for release by the Managing Director & CEO, Richard Valencia.

Contact Details

Investor Relations Contact:

Hannah Howlett
WE Communications
T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com



About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.